Skip to main content
. 2020 Nov 19;107(1):187–200. doi: 10.3324/haematol.2020.267500

Figure 5.

Figure 5.

miR-based overall survival score for T-cell prolymphocytic leukemia (miROS-T-PLL) stratifies patients based on miR-200a-3p, miR-223-3p, and miR-424-5p expression. (A to D) Associations of microRNA (miR) expression with overall survival (OS) from diagnosis (see Online Supplementary Table S12 for the comprehensive dataset). (A) miR-98-3p (median OS high vs. low expression: 16.3 months vs. 29.4 months, P=0.0008, log-rank test); (B) miR-200a-3p (median OS high vs. low expression: 52.7 months vs. 19.1 months, P=0.001, log-rank test); (C) miR-223-3p (median OS high vs. low expression: 14.9 months vs. 26.0 months, P=0.001, log-rank test), and (D) miR-424-5p (median OS high vs. low expression: 14.4 months vs. 26 months, P=0.0007, log-rank test) were most significantly associated with OS, when comparing the tertile of T-PLL patients with the highest expression to the tertile with the lowest expression of the respective miR. (E) Analysis via training (n=22) and validation data sets (n=22): optimum thresholds were calculated by recursive partitioning for all possible combinations of miR-200a-3p, miR-223-3p, and miR-424-5p expression levels, adding one point to the total score if the respective expression cutoff was passed. Best results were obtained using the following thresholds: miR-200a-3b: fold change (fc)<2.21, miR-223-3p: fc ≥9.8, miR-424-5p: fc≥0.91 (fc relative to CD3+ pan-T cells derived from healthy donors) and a cutoff of ≥2 points. A significant OS association was observed in the validation set (P=0.0004, log-rank test) as well as (E) in the total cohort of 44 T-PLL patients (median OS high vs. low expression: 14.4 months vs. 29.4 months, P<0.0001, log-rank test).